Pacer Advisors, Inc. Catalyst Pharmaceuticals, Inc. Transaction History
Pacer Advisors, Inc.
- $39 Billion
- Q2 2024
A detailed history of Pacer Advisors, Inc. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Pacer Advisors, Inc. holds 2,967,575 shares of CPRX stock, worth $59 Million. This represents 0.12% of its overall portfolio holdings.
Number of Shares
2,967,575
Previous 2,265
130918.76%
Holding current value
$59 Million
Previous $36,000
127586.11%
% of portfolio
0.12%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CPRX
# of Institutions
285Shares Held
96.6MCall Options Held
29.2KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$372 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY9.13MShares$181 Million2.97% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.1MShares$161 Million0.0% of portfolio
-
State Street Corp Boston, MA6.03MShares$120 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3MShares$59.7 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.04B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...